Stephen Robinson (he/him) π³οΈβπ
@RobinsonLab_QIB
Followers
1K
Following
4K
Media
58
Statuses
897
Research Group Leader at The Quadram Institute and Senior Lecturer at the University of East Anglia.
Norwich, UK
Joined July 2012
Neuropilin 2 stabilises adherens junctions and protects against endothelial activation by promoting the interaction between VE ... https://t.co/DlziSwps2I
#biorxiv_cellbio
biorxiv.org
The mechanosensing properties of endothelial cell-cell junctions are essential for vascular beds to respond to the mechanical forces exerted by blood flow. In states of disturbed flow, endothelial...
1
1
2
Very excited to share our latest paper describing crosstalk between Ξ±vΞ²6 integrin & HER2 in breast cancer invasion & drug resistance. Great work by @HJMald & many others https://t.co/PdTG1XsPZE
@ScienceAdvances @LivUniISMIB @AdamHurlstone Many thanks to @BCCare @NorthWestCancer
science.org
Control of Ξ±VΞ²6 integrin and HER2 trafficking drives breast cancer invasion, drug resistance, and therapeutic response.
4
6
13
Paper from my #PhD is out! We profiled the gut and oral #microbiome of metastatic #breastcancer patients. This project was a long one in collaboration with @wearemedsir. Thanks @TheQuadram @bigctweets for supporting my studentship. It's published π. https://t.co/cYXNwRrnJz
2
3
9
Delighted to share that Iβll be joining the @QuadramInstitute as Director & CEO in April 2025! I am honoured to work with an incredible team and partners to push the boundaries of gut health, microbiology, and food science research.
π We are delighted to announce the appointment of Professor @DanielFigeys as our new Director and Chief Executive. https://t.co/8T2knTzqC0
11
10
72
π₯³I'm incredibly honoured to receive the @MicrobioSoc Peter Wildy Prize 2025 for #scicomm, a true team prize! Huge thanks to those who nominated me & to incredible collaborators & team members. So many people to thank - I'll be highlighting them all in my prize lecture!π¦
Peter Wildy Prize 2025: Professor Lindsay Hall (@hall_lab), University of Birmingham, UK (@unibirmingham)
33
18
194
I'm glad I don't have to write an endorsement piece, because I really wouldn't know how to go about it. Ever since 2015, when Trump descended the escalator, I have had the same feeling, which I've never quite seen articulated, so I will briefly try:
982
7K
38K
π¨ Exciting opportunity at @unibirmingham @unibirm_CMH! π¨ Offering a 2-year Springboard Fellowship designed to support high-calibre #PDRA researchers in developing strong proposals for fellowships like ERC Starter Grants, Future Leaders Fellowship, Wellcome/MRC CDA, and more.
1
22
22
Check out this exciting thread featuring a new preprint from @RobinsonLab_QIB π Thrilled to share our collaborative study on #Bifido and #BreastCancer, now preprinted! We explore the "sweet spot" of EPS-driven #anticancer immune mechanisms. #GutHealth #CancerResearch
𧡠Exciting new preprint! π¨ Weβve uncovered how Bifidobacterium pseudocatenulatum capsular exopolysaccharides (EPS) can enhance systemic anti-tumour immunity in pre-clinical breast cancer models. Here's what we found π #cancerresearch #microbiome
0
3
18
Check out the full preprint for more details! 𧬠#cancerimmunology:
0
0
1
3/ Think of it as bacteria with a βsweeterβ edge - the sugars in the EPS are driving immune responses that fight tumours. This unique mechanism positions Bifidobacterium EPS as a potential new class of therapeutic compounds in cancer treatment. π₯ #immunotherapy
1
0
1
2/ A standout feature? The bacterial capsular EPS produced by B. pseudocatenulatum 210. EPS activates dendritic cells and boosts systemic cDC1 infiltration, triggering a powerful CD8+ T cell-mediated anti-tumour response. π¬π¦
1
0
1
1/ Gut microbes have long been recognised as key regulators of cancer responses. Our study highlights the potential of B. pseudocatenulatum to inhibit breast cancer progression, enhancing the efficacy of standard therapies in pre-clinical mouse models.
1
0
1
𧡠Exciting new preprint! π¨ Weβve uncovered how Bifidobacterium pseudocatenulatum capsular exopolysaccharides (EPS) can enhance systemic anti-tumour immunity in pre-clinical breast cancer models. Here's what we found π #cancerresearch #microbiome
2
5
9
SO pleased to see this study now published @MolMetab - led by the fantastic @JLopTello! Jorge is currently setting up his own lab @UAM_Medicina so definitely keep an πout for further exciting work in this area and research opportunities!
Our study on maternal gut Bifidobacterium and its impact on fetal brain metabolism is out today in @MolMetab. Another fantastic collaboration with @PerriLab and @hall_lab. Here's a summary of our work over the past few years! #microbiota @CTR_Cambridge
https://t.co/uolLnhQm1N
1
3
17
In vitro and in vivo data demonstrate neuropilins regulate the trafficking of alpha5-integrin in endothelial cells. @RobinsonLab_QIB
https://t.co/M9mdIZa3Bg
nature.com
Communications Biology - In vitro and in vivo data demonstrate that neuropilins regulate the trafficking of alpha5-integrin in endothelial cells.
0
3
5
@JCIHorton @pintofscience Dr. Chris Price from @RobinsonLab_QIB @TheQuadram talks about why he studies gut bacteria & how bacteria from infants could generate the next wave of cancer drugs. @pintofscience #pint24 #pint24Norwich
1
6
9
Weβre looking for a Research Scientist to join @RobinsonLab_QIB to work on a @BreastCancerNow funded project examining the microbiome of patients with hormone receptor positive breast cancer. π· Β£35,300 to Β£43,750 ποΈ Apply by 12 March 2024 β‘οΈ https://t.co/rLmXf97LA9
0
8
11
Do you have a PhD in cell or molecular biology with previous experience in bioinformatic analyses of microbiota samples?𧬠Check out our current vacancy in @RobinsonLab_QIB β€΅οΈ π· Β£35,300 to Β£43,750 ποΈ Apply by 12 March 2024 β‘οΈ https://t.co/zBkPPjrTLG
2
10
14
To celebrate the publication of the KILLING JERICHO paperback, Iβm giving away a SIGNED & DEDICATED copy of the hardback! Open only for the next 24 hrs. To enter simply follow me, like & retweet this post! Winner limited to UK only - announced tomorrow at 7pm! #KillingJericho
65
313
383